Sickle Cell Disease Drugs Market Share

Regionally, sickle cell disease drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is anticipated to account for largest revenue share by 2036, on the back of advanced medical facilities, and research and development activities. Moreover, the increasing government investment in healthcare sector and favorable reimbursement policies is estimated to boost the regional market growth. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America. As pr another report by WHO, the per capita healthcare expenditure of North America valued USD 10,050.279, in the same year. The market in the Asia Pacific is estimated to witness notable growth accounting to the increasing population and prevalence of sickle cell disease in the region. Furthermore, constant development in the public healthcare system, along with the economic development in the APAC region also tends to positively influence the market growth.